Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

Diabetes and Metabolism

Volumn 39, Issue 6, 2013, Pages 524-531

  Hensen, J ^a   Howard, C P ^b   Walter, V ^b   Thuren, T ^b  

^a NORDSTADT HOSPITAL   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Canakinumab; Diabetes mellitus; Interleukin 1 ; Metformin; Monoclonal antibody

Indexed keywords

C PEPTIDE; CANAKINUMAB; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1BETA ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CRYSTALLURIA; DIABETES CONTROL; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ERYTHEMA; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDRONEPHROSIS; INFECTION; INFESTATION; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; KIDNEY CYST; KIDNEY DISEASE; KIDNEY TUMOR; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SWELLING; THROMBOCYTOPENIA; URETER STONE; URINARY TRACT DISEASE; URINARY TRACT INFECTION;

ANTICORPS MONOCLONAL; CANAKINUMAB; DIABETES MELLITUS; DIABÈTE SUCRÉ; INTERLEUKIN-1Β; INTERLEUKINE-1Β; METFORMIN; METFORMINE; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1BETA; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887618957     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.07.003     Document Type: Article

References (27)

1. Steinberg B.A., Bhatt D.L., Mehta S., Poole-Wilson P.A., O'Hagan P., Montalescot G., et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008, 156:719-727.
2. Bonora E. Protection of pancreatic beta-cells: is it feasible?. Nutr Metab Cardiovasc Dis 2008, 18:74-83.
3. Rosenstock J., Goldstein B.J., Vinik A.I., Colleen O'Neill M., Porter L.E., Heise M.A., et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs SULphonylurea Titration (result) study. Diabetes Obes Metab 2006, 8:49-57.
4. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
5. Ahrén B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
6. Wajchenberg B.L. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
7. Masters S.L., Latz E., O'Neill L.A. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med 2011, 3:81ps17.
8. Pietropaolo M., Barinas-Mitchell E., Pietropaolo S.L., Kuller L.H., Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000, 49:32-38.
9. Bendtzen K., Mandrup-Poulsen T., Nerup J., Nielsen J.H., Dinarello C.A., Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986, 232:1545-1547.
10. Dinarello C.A., Donath M.Y., Mandrup-Poulsen T. Role of IL-1β in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010, 17:314-321.
11. Börjesson A., Carlsson C. Altered proinsulin conversion in rat pancreatic islets exposed long-term to various glucose concentrations or interleukin-1β. J Endocrinol 2007, 192:381-387.
12. Emanuelli B., Glondu M., Filloux C., Peraldi P., Van Obberghen E. The potential role of SOCS-3 in the interleukin-1β-induced desensitization of insulin signaling in pancreatic β-cells. Diabetes 2004, 53(Suppl. 3):S97-S103.
13. Venieratos P.D., Drossopoulou G.I., Kapodistria K.D., Tsilibary E.C., Kitsiou P.V. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1β and suppressor of cytokine signalling-1 in mouse pancreatic beta cells. Cell Signal 2010, 22:791-800.
14. Böni-Schnetzler M., Boller S., Debray S., Bouzakri K., Meier D.T., Prazak R., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
15. Mandrup-Poulsen T., Pickersgill L., Donath M.Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010, 6:158-166.
16. Böni-Schnetzler M., Thorne J., Parnaud G., Marselli L., Ehses J.A., Kerr-Conte J., et al. Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008, 93:4065-4074.
17. Ehses J.A., Lacraz G., Giroix M.H., Schmidlin F., Coulaud J., Kassis N., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009, 106:13998-14003.
18. Osborn O., Brownell S.E., Sanchez-Alavez M., Salomon D., Gram H., Bartfai T. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 2008, 44:141-148.
19. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
20. Sloan-Lancaster J., Abu-Raddad E., Polzer J., Miller J.W., Scherer J.C., De Gaetano A., et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 2013, [Epub ahead of print]. 10.2337/dc12-1835.
21. Ilaris [package insert] 2009, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
22. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
23. Alten R., Gram H., Joosten L.A., van den Berg W.B., Sieper J., Wassenberg S., et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R67.
24. So A., De Meulemeester M., Pikhlak A., Yücel A.E., Richard D., Murphy V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
25. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-2406.
26. Ridker P.M., Howard C.P., Walter V., Everett B., Libby P., Hensen J., et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.
27. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.